
You choose the disease, we find the drug. Those are the main bullet points from a new major collaboration deal between Danish biotech Santaris Pharma and international pharmaceutical group Bristol-Myers Squibb (BMS), according to the Danish business daily, Børsen.
Santaris will receive USD 10m up-front and could earn an additional 90 million in milestone payments, in return for making its technology platform, LNA, and employees available to BMS in their search for novel drugs.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app